CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
24,468
24,468
29,115
31,830
37,975
Selling general and administrative
8,097
8,097
9,515
11,930
10,879
Total operating expenses
32,565
32,565
38,630
43,760
48,854
Operating income or loss
-32,565
-32,565
-38,630
-43,760
-48,854
Interest expense
-
-
15
-
-
Total other income/expenses net
-9,396
-9,396
-4,596
37,225
-
Income before tax
-41,307
-41,307
-43,241
-5,995
-46,672
Income from continuing operations
-41,307
-41,307
-43,241
-5,995
-46,672
Net income
-41,307
-41,307
-43,241
-5,995
-46,672
Net income available to common shareholders
-41,307
-41,307
-43,241
-5,995
-46,672
Basic EPS
-
-0.89
-1.03
-0.20
-1.59
Diluted EPS
-
-0.89
-1.03
-0.20
-1.59
Basic average shares
-
46,554
41,854
29,479
29,350
Diluted average shares
-
46,554
41,854
29,479
29,350
EBITDA
-
-32,565
-43,226
-43,760
-48,854